Apr 06, 2020
The Global Pulmonary Arterial Hypertension Market is expected to grow from USD 7,196.48 Million in 2019 to USD 9,925.12 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.50%
Jan 15, 2020
Visiongain Publishes Global Pulmonary Arterial Hypertension Market 2019-2029 Report
Sep 12, 2019
Correvio Highlights FDA Acceptance of United Therapeutics' Trevyent New Drug Application
Jun 26, 2019
Orenitram (treprostinil; United Therapeutics) Market Overview - Newer Brand Uptravi (selexipag; Johnson & Johnson/Nippon Shinyaku) Poses Tough Competition in the Oral Prostacyclin Class
Jun 26, 2019
Remodulin (treprostinil; United Therapeutics/Mochida) Overview: United Therapeutics is Developing Three New Formulations of Remodulin to Overcome Administration Difficulties
May 29, 2019
The global pulmonary arterial hypertension market size is expected to reach USD 9.3 billion by 2026
Oct 02, 2018
Arena Pharmaceuticals Reports Positive Long-Term Data from the Ongoing Open-Label Extension of the Phase 2 Trial Evaluating Ralinepag for Treatment of Pulmonary Arterial Hypertension
Aug 28, 2018
Arena Pharmaceuticals Presented Phase 1 Clinical Data for Ralinepag in Pulmonary Arterial Hypertension at the European Society of Cardiology
Jan 03, 2018
Corsair Pharma and United Therapeutics Enter into Strategic Collaboration to Advance Novel Treprostinil Prodrugs
Oct 19, 2017
Arena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients with Pulmonary Arterial Hypertension at the American College of Chest Physicians 2017 Annual Meeting
Sep 06, 2017
Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at International Congress of the European Respiratory Society
Jun 29, 2017
Arena Pharmaceuticals Completes Trial Comparing Once-Daily, Extended Release Formulation of Ralinepag with Twice-Daily, Immediate Release Formulation in Normal Healthy Volunteers